In recent years, the prognosis of chronic myeloid leukemia (CML) has been greatly improved
either with interferon-(IFN-) therapy or allogeneic bone marrow transplantation (BMT). In …

Interferon (IFN) therapy has become widely used for the treatment of chronic myelogenous
leukemia. Hematologic remissions can be induced in about 60% of patients. Moreover, in a …

In chronic myelogenous leukemia (CML), amplification of a segment of bcr-abl messenger
RNA (mRNA) by polymerase chain reaction (PCR) can be used to detect minimal residual …

Blood ASH 96/2 treatment with BMT, and serial samples were analyzed for levels of
genomic and mRNA BCR-ABL using DNA-PCR with patientspecific primers and RT-PCR …

The discovery of the BCR-ABL fusion gene on the Philadelphia (Ph) chromosome in 1985
was the start of a new era in understanding the molecular basis of hematologic …

PURPOSE: To document the characteristics of patients with major breakpoint cluster region
(M-bcr) rearrangement–negative chronic myelogenous leukemia (CML). PATIENTS AND …

We measured using a competitive quantitative polymerase chain reaction-capillary
electrophoresis (PCR-CE)-based assay, the levels of bcr-abl transcripts in 44 patients with …

To determine the source of residual disease detected in patients with chronic myeloid
leukaemia (CML) in complete cytogenetic remission (n= 8) after treatment with interferon‐α …

A substantial minority of patients with chronic myelogenous leukemia (CML) achieve a
complete response (CR) to treatment with interferon-(IFN), defined as the disappearance …

Chronic myelogenous leukemia involves clonal expansion of hematopoietic progenitor cells
associated with the characteristic translocation between chromosomes 9 and 22, resulting in …